Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

NCT04958967 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The protocol need to review

Conditions

Interventions

Sponsor

Allist Pharmaceuticals, Inc.